ER-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough breast cancer
Disease control CompletedThis study tested a new two-drug combination (samuraciclib and elacestrant) in 49 adults with a common type of advanced breast cancer (HR+/HER2-). The goal was to find a safe dose and see if it can slow the cancer's growth. Participants had already tried other treatments and thei…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can electronic health records replicate Gold-Standard cancer trials?
Knowledge-focused CompletedThis completed study looked at over 6,000 people with advanced breast cancer to see if information from electronic health records could match the results of a famous clinical trial called PALOMA-2. The goal was not to test a new drug, but to learn whether real-world data can be t…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC